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Background: To compare the 6-month results of two formulations of Riboflavin provided by Sina Darou, Iran, and
Uznach, Switzerland, in corneal collagen cross-linking (CXL) for keratoconus patients.
Findings: Considering the results of the previous study about the similarity of the formulations and the active
ingredients of the two types of Riboflavin, they were used in the CXL procedure of 60 keratoconic eyes (30 eyes in
each group). After 6 months, the mean improvement of UCVA (0.239), BCVA (0.707), and MRSE (0.513) did not differ
significantly between the two groups. The mean decrease in max- K (0.731), mean- K (0.264), central corneal
thickness (0.759), and Q-value (0.669) did not show any significant difference between the two groups. The two
groups had no significant difference in endothelial cell count decrease (0.229). The Sina Darou formulation
decreased corneal hysteresis more than the Swiss formulation (P = 0.057) but there were no significant differences
in the mean decrease of corneal resistance factor between the two groups (P = 0.117).
Conclusions: Based on the early results, the results of visual acuity, refraction, and corneal topography using Sina
Darou and Uznach formulations of Riboflavin showed that both were effective in CXL. However, considering the
relatively significant difference in corneal hysteresis changes between the two groups, this study will continue to
report the long-term results.
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Collagen cross linking (CXL) with Riboflavin has shown
desirable effects on the arrest of keratoconus [1-3]. In
this procedure, riboflavin produces free radicals under
the effect of UV. These radicals create new covalent
bonds in the stroma which strengthen the corneal tissue
[1]. Riboflavin enhances UVA absorbance as a photosen-
sitizer [4] and reduces cellular damage [5]. Therefore,
the use of riboflavin in CXL is of extreme importance.
In a primary study, we showed that the formulation and
the amount of the active ingredient of riboflavin pro-
duced in Sina Darou, Iran, were similar to riboflavin pro-
duced in Uznach, Switzerland. Fluorometry and high* Correspondence: hhashemi@norc.ac.ir
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unless otherwise stated.performance liquid chromatography were used to compare
the amount of the active ingredient of the two products.
After calculating the area under curve of the absorption
rate of the active ingredient of the two products, statistical
analysis showed no significant difference between them. In
the present study, the efficacy of the two pharmaceutical
products was compared in order to recommend the use of
the Iranian product, which is more available and has lower
costs, instead of the Swiss product.Finding
Methods
In this parallel clinical trial, 60 eyes of 60 keratoconus
patients that received CXL were compared in two
groups. The flowchart of the passage of participants is
shown in Figure 1. Iranian riboflavin 0.1% (Sina Darou,
Iran) was used during CXL in group A and Swissal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow Diagram of the passage of participants.
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Switzerland) was used in group B. The patients were al-
located to the groups consecutively. The inclusion cri-
teria were the clinical and paraclinical diagnosis of
progressive keratoconus, age 15–35 years, keratometry
less than 55 D, and a central corneal thickness (CCT)
more than 400 micron. Patients with other ocular dis-
eases or a history of ocular surgery were excluded from
the study. Participants discontinued the use of the hard
and soft contact lens 3 weeks and 3 days prior to the
surgery, respectively.
At first, a written informed consent was obtained from
each participant. Noor review board approved the study.
Iranian Registry of Clinical Trials also approved the
study (registration number: IRCT201212034333N2).
The method of the surgery has been already reported
[3]. After local anesthesia, the epithelium of the central
7 mm of the cornea was removed in 3–4 vertical strips
that measured about 2 mm in width sparing a strip
measuring approximately 1 mm. An epithelial strip was
also horizontally removed from the lower one third of
the cornea. Then, Iranian or Swiss riboflavin 0.1% drops
in dextran 20% were instilled on the cornea every 3 mi-
nutes for 30 minutes in the intervention and control
group, respectively. After the saturation of riboflavin in
the anterior chamber, irradiation (wavelength 370 nm,power 3 mW/cm2) was started at 5 cm using UVX sys-
tem (IROC, Zürich, Switzerland). During 30 minutes of
irradiation, riboflavin instillation was repeated every
three minutes. Then, the corneal surface was irrigated
with sterile balanced saline solution, a soft bandage con-
tact lens (Night & Day, Ciba Vision, Duluth, GA) was
placed on it, and chloramphenicol 0.5% (Sina Darou,
Iran) was administered. Post surgical regimen included
chloramphenicol 0.5% four times daily, betamethasone
0.1% (Sina Darou, Iran), and preservative free artificial
tears (Hypromelose, preservative free) as required. The
patients were examined on days 1 and 3 after surgery,
and the lens was removed if healing was observed. After
removing the lens, chloramphenicol was discontinued
while betamethasone twice daily was continued for an-
other week. If epithelial healing was not observed, daily
visits continued until the epithelium healed completely.
No complications were noticed during or after surgery.
Corneal haze related to the surgery was completely re-
moved before the third month.
The patients received ophthalmic examination and
paraclinical evaluation before the procedure and 1, 3,
and 6 months after it. Paraclinical tests included uncor-
rected visual acuity (UCVA) and best spectacle corrected
visual acuity (BSCVA) using a Snellen chart, and mani-
fest refraction spherical equivalent (MRSE) using an
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Pentacam (Oculus Optikgerate GmbH, Germany) to
evaluate corneal topographic indices, an ocular response
analyzer (ORA; Reichert Ophthalmic Instruments, Buf-
falo, USA) to assess corneal biomechanical properties,
and a non-contact specular microscope (Konan Medical,
Hyogo, Japan) to investigate endothelial cell count
(ECC). The corneal biomechanical properties and ECC
were evaluated twice, once before the surgery and once
six months after the procedure.
We used repeated measure analysis of variance to
evaluate the trend of the changes in each group and be-
tween the two groups. The results are shown as mean ±
SD. The level of significance was set at 0.05.Results
Sixty eyes of 60 patients (60% male) with a mean age of
24.32 ± 4.59 were evaluated. The patients received Iranian
(group A) and Swiss (group B) riboflavin in 2 groups. The
differences of all of the baseline indices were not statisti-
cally significant between the two groups.
The mean UCVA showed an improving trend in group
A until the end of the 6th month (P = 0.168) while in
group B, it resumed its improving trend after a decrease
in the third month (P = 0.577). The trend of the 6-month
results did now a significant difference between the two
groups (P = 0.239). The mean BCVA showed a decrease in
both groups one month after the procedure but improved
afterwards, although it was not significant. The trend of
the BCVA changes was not significant between the two
groups (P = 0.707).
After 6 months, MRSE decreased in group A but
remained stable in group B. In general, the mean 6-month
changes of MRSE was not significant between the two
groups (P = 0.513). The trend of the changes of the above-
mentioned indices is shown in Table 1.Table 1 Comparison of the results between two groups of ke
Riboflavin No of eyes Pr
UCVA (logMAR)
Sina Darou, Iran 30
Uznach, Switzerland 30
BCVA (logMAR)
Sina Darou, Iran 30
Uznach, Switzerland 30
Sphere (diopter)
Sina Darou, Iran 30 −
Uznach, Switzerland 30 −
Cylinder (diopter)
Sina Darou, Iran 30 −
Uznach, Switzerland 30 −
Spherical equivalent (diopter)
Sina Darou, Iran 30 −
Uznach, Switzerland 30 −
*Related to the comparison of the trend of the changes between the two groups uDespite an increase in max-K in the first follow up, it
had a decreasing trend thereafter. The flattening was sig-
nificant in neither group. In general, the decreasing
trend of max-K was similar in both groups until the end
of the sixth month (P = 0.731). Mean-K also showed the
same decreasing trend with no significant difference be-
tween the two groups (P = 0.264). CCT showed a small
insignificant decrease in both groups with no significant
difference in 6 months (P = 0.759). The Q-value insig-
nificantly shifted toward a prolate shape (more positive)
in both groups but the 6-month trend of the changes
showed no significant difference between the two groups
(P = 0.669) (Figure 2).
Mean ± SD of corneal hysteresis (CH) was 7.70 ± 1.63
before the procedure in Group A which decreased to
6.76 ± 1.54 mmHg six months after the surgery (P =
0.008). In group B, CH decreased from 7.38 ± 2.10 to
7.23 ± 1.56 mmHg (P = 0.630). The decrease in CH be-
tween the two groups was borderline significant (P =
0.057).
Mean ± SD of corneal resistance factor (CRF) de-
creased from 7.02 ± 1.90 to 6.32 ± 1.30 mmHg in group
A (P = 1.000) and from 6.80 ± 2.03 to 6.80 ± 1.84 mmHg
in group B (P = 1.000); the difference between the two
groups was not significant (P = 0.117).
The mean ± SD of ECC in group A was 2815.4 ± 243.1
and 2415.8 ± 317.8 cell/mm2 before and after the sur-
gery, respectively (P < 0.001). In group B, ECC decreased
from 2751.0 ± 261.2 to 2467.0 ± 255.9 cell/mm2 (P <
0.001). The decrease in ECC showed no significant dif-
ference between the two groups (P = 0.229).
Discussion
CXL decreases or arrests the progression of keratoconus.
After CXL, the corneal rigidity increases by up to 4.5 times
[6] and the effects of the strengthening remain for a long
time [2,3]. Although there are still concerns regardingratoconus patients receiving Iranian and Swiss riboflavin
After surgery P-
value*e operation 1 months 3 months 6 months
0.82 ± 0.66 0.60 ± 0.52 0.52 ± 0.39 0.45 ± 0.36
0.239
0.82 ± 0.55 0.67 ± 0.54 0.79 ± 0.54 0.73 ± 0.51
0.23 ± 0.28 0.25 ± 0.21 0.24 ± 0.19 0.19 ± 0.13
0.707
0.22 ± 0.18 0.27 ± 0.22 0.24 ± 0.19 0.20 ± 0.21
1.53 ± 2.56 −1.70 ± 2.43 −1.80 ± 2.45 −1.42 ± 2.36
0.937
1.59 ± 1.82 −1.64 ± 2.45 −1.57 ± 2.33 −1.63 ± 2.33
2.48 ± 1.77 −2.93 ± 2.07 −2.17 ± 2.17 −2.36 ± 1.79
0.242
2.65 ± 1.94 −2.83 ± 1.88 −3.20 ± 2.04 −2.77 ± 1.93
2.77 ± 2.51 −3.16 ± 3.02 −2.88 ± 3.13 −2.60 ± 2.85
0.513
2.96 ± 2.28 −3.10 ± 2.78 −3.16 ± 2.75 −3.01 ± 2.70
sing repeated measure ANOVA.
Figure 2 The temporal changes of max-K, mean-K, corneal thickness and Q-value between two groups of keratoconus patients receiving
Iranian and Swiss riboflavin.
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the cornea [7,8], the 5-year results of treatment [3] can re-
duce the concern to a great extent. In this procedure, ribo-
flavin produces free radicals under the effect of UV. These
radicals create new covalent bonds in the stroma which
strengthen the corneal tissue [1].
The role of riboflavin in this procedure is to increase
UV absorbance and protection against its destructive ef-
fects on the cornea and lower layers. In vivo, riboflavin
decreases the cytotoxic effects of UVA by up to 10 times
[5]. On the other hand, it increases UV absorbance by
up to 95% [4]. Without riboflavin, only 25-35% of UV is
absorbed in the cornea [9] and reaches 50% in the lens
which is undesirable [10]. This absorbance rate is influ-
enced by riboflavin concentration. UV absorbance in-
creases linearly in concentrations up to 0.04% while
higher concentrations have no effect on absorbance [11].
CXL is considered a desirable treatment option and
besides efficacy, it minimizes the cytotoxic effects on the
epithelium with no cellular damage in the corneal endo-
thelium and lens. During the procedure, epithelial cellu-
lar death occurs to a depth of approximately 300
micron; however, due to their high repopulation prop-
erty, they regenerate after 6 months [12-14] with no dra-
matic effects on the treatment outcome [15,16]. On the
other hand, the regeneration speed is very low in the
endothelial cells and their damage is irreversible [11].
Clinical studies have shown that the cellular damage of
CXL in the epithelium is within acceptable ranges and
have reported no pathological damage from the endo-
thelium to the retina after CXL [11,16,17]. Therefore,
riboflavin is a mainstay of treatment.
Imported riboflavin is now used in Iran. Easier accessi-
bility and lower costs persuaded us to use the Iranian
riboflavin (Sina Darou). A preliminary study showed thatboth drugs were similar in formulation and active
ingredient.
The clinical use of the drug in our study showed its ef-
ficacy, and the trend of the changes of vision, refraction,
and topography was similar in both groups. In other
words, although refraction, vision, and keratometry of
the patients were deteriorating in the past year, develop-
ment of the collagen bands arrested the process
6 months after the surgery with even improvement in
some patients. The rate of the changes was similar in
both groups, and also similar to a previous study we
conducted using Swiss riboflavin [3]. Some studies re-
ported that vision and refraction remained stable with-
out significant changes [18] while some other studies
reported a significant improvement in vision and refrac-
tion [19,20]. Of course, differences in the follow-up
period, participants’ age, and study population may be
the reasons for the different results.
In shorter follow-up, it should be kept in mind that
the results of paraclinical tests may be affected by the
corneal haze of CXL.
In our study, corneal keratometry changed similarly in
both groups, showing that the process of protrusion and
steepening stopped similarly in both treatment groups.
Therefore, the inter- and intra-fibril bands were well de-
veloped in the group that received Iranian riboflavin.
Wollensak et al. [1] reported that max-K decreased by
2.01 D in a follow-up period of 3 months to 4 years. In
our study, the decrease was 0.6 and 0.3D in the Iranian
and Swiss riboflavin groups, respectively. The reason for
the difference could be different surgical methods; wol-
lensak et al. removed the 7 mm central cornea while we
removed a number of epithelial strips. Comparative
studies should be designed and performed to evaluate
this hypothesis.
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that received Iranian riboflavin. Since the cytotoxic ef-
fects of the procedure on the epithelial cells continues
for up to 6 months [12-14], the results of the procedure
after one year or more should be used to evaluate CH,
CRF, and ECC changes.
Of course, it should be noticed that despite laboratory
reports of increased corneal rigidity following CXL, nu-
merous clinical studies have found no change in the cor-
neal biomechanical properties after CXL and different
follow-ups have shown that the corneal biomechanical
changes are stable without improvement [21-26].
Conclusion
In general, it could be stated that vision, refraction, and
corneal topography following CXL using Iranian (Sina
Darou) and Swiss riboflavin are similar based on the 6-
month results. However, considering the different de-
creases in CH, we require long-term studies to replace
Swiss riboflavin with the Iranian one. Therefore, this
study will continue to report the long-term results.
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